These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17942451)

  • 1. Role of antibody therapy in lymphoid malignancies.
    Dearden CE
    Br Med Bull; 2007; 83():275-90. PubMed ID: 17942451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody therapy for B-cell malignancies.
    Cheson BD
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S2-14. PubMed ID: 16720198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ten years since the successful introduction of the first monoclonal antibody (rituximab) into the therapy of lymphomas].
    Trnený M; Klener P
    Cas Lek Cesk; 2007; 146(7):578-85. PubMed ID: 17722844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody therapy of haematological malignancies.
    Dearden C
    BioDrugs; 2002; 16(4):283-301. PubMed ID: 12196040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F; O'brien S
    Cancer Invest; 2006 Nov; 24(7):718-25. PubMed ID: 17118783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Innovative antibody-therapies for malignant lymphomas].
    Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
    Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of hematopoietic malignancies.
    Houghton A; Scheinberg D
    Semin Hematol; 1988 Jul; 25(3 Suppl 3):23-9. PubMed ID: 3051406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells.
    Stanglmaier M; Reis S; Hallek M
    Ann Hematol; 2004 Oct; 83(10):634-45. PubMed ID: 15309525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.
    Dyer MJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):52-7. PubMed ID: 10561018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody therapy in lymphoid malignancies.
    Hainsworth JD
    Oncologist; 2000; 5(5):376-84. PubMed ID: 11040273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of monoclonal antibody therapy for malignant lymphoma].
    Ogura M
    Nihon Rinsho; 2002 Mar; 60(3):505-16. PubMed ID: 11904966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies in the treatment of malignant lymphoma].
    Niu Y; Shi YK
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):435-41. PubMed ID: 16900652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
    Waldmann TA
    Oncogene; 2007 May; 26(25):3699-703. PubMed ID: 17530023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
    Tobinai K
    Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody as therapy for malignant lymphomas.
    Coiffier B
    C R Biol; 2006 Apr; 329(4):241-54. PubMed ID: 16644494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.